Breast cancer is the most common cancer for women. The incidence is increasing year by year. It plays an important role in the overall treatment of breast cancer in advanced chemotherapy stage. It is important to choose the ideal chemotherapy. Docetaxel and doxorubicin is the most effective drug for treatment of breast cancer and it is widely used in for breast cancer chemotherapy. The programs do research in efficacy and safety of docetaxel and epirubicin in treatment of patients with advanced breast cancer

For the disease of the breast, it is still generally accepted by the people, it is important for the treatment of breast cancer has been widely accepted. Docetaxel is a new generation semi-synthetic anti-cancer drug law, the Ministry is to strengthen the mechanisms through its effects on microtubules or microtubule system cents of tubulin, the assembly of microtubules and prevents multi-process, cells of block stable microtubules in G2-M phase and inhibits proliferation of tumor cells and mitosis. Docetaxel and paclitaxel concentration in the cells three times, and lived in the cell. In vivo in the rat colon, breast, lung, ovarian xenograft, cisplatin, etoposide, fluorouracil and paclitaxel against a cell line cross-resistance. Clinical trials indicate that adjuvant chemotherapy with docetaxel for early breast cancer can improve survival and the risk of relapse. Epirubicin and doxorubicin bone marrow toxicity and antitumor activity in the heart of the much lower cost, is only 42% compared with a success rate of breast cancer. Table of doxorubicin and docetaxel in advanced breast cancer showed a lower toxicity in the blood.

Pharmaceutical raw materials suppliers’ studies have shown that several treatments for breast cancer with epirubicin, docetaxel in advanced stages, the rate was 7.14% CR and PR was 48.21%, 55.36% efficiency in general, than literature reports, just west of the plant and the effectiveness of treatment has shown that epirubicin as advanced breast cancer can improve the overall efficiency in the clinical treatment of breast cancer in an advanced stage. Moreover, the high toxicity of combination chemotherapy in the bone marrow and the gastrointestinal tract, the frequency was slightly lower than the price of the literature was generally mild, but does not prevent the factors of dose.

In summary, the combination of doxorubicin and docetaxel is a good program for the treatment of advanced breast cancer, in particular in patients with recurrent and non-treated, it has similar efficacy. But their toxicity is tolerated and has no side effects. Therefore scientists provisionally conclude that docetaxel and epirubicin is effective in the treatment of advanced breast cancer. Of course, it needs more clinical observations for precise effects of the drug in advanced breast.

Source:http://www.cospcn.com